ID
31385
Description
Study ID: 104507 Clinical Study ID: BEX104507 Study Title: Phase II Study of Iodine-131 Anti-B1 Antibody for Non Hodgkin’s Lymphoma Patients who have Previously Received Rituximab Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00996593 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: tositumomab Trade Name: Bexxar Study Indication: Lymphoma, Non-Hodgkin
Keywords
Versions (2)
- 8/6/18 8/6/18 -
- 8/18/18 8/18/18 -
Copyright Holder
GlaxoSmithKline
Uploaded on
August 18, 2018
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
Iodine-131 Anti-B1 Antibody for Non Hodgkin’s Lymphomas NCT00996593
Independent Response Evaluation Oncologist's Assessment and Consensus Criteria
Description
Consensus Criteria
Alias
- UMLS CUI-1
- C0376298
- UMLS CUI-2
- C0243161
Description
Response to treatment; Date in time
Data type
date
Alias
- UMLS CUI [1,1]
- C0521982
- UMLS CUI [1,2]
- C0011008
Description
Consensus; Response to treatment
Data type
text
Alias
- UMLS CUI [1,1]
- C0376298
- UMLS CUI [1,2]
- C0521982
Description
Comments
Data type
text
Alias
- UMLS CUI [1]
- C0947611
Description
Administrative
Alias
- UMLS CUI-1
- C1320722
Similar models
Independent Response Evaluation Oncologist's Assessment and Consensus Criteria
C0011008 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,2])
C0521982 (UMLS CUI [1,2])
C1519316 (UMLS CUI [1,2])